Description

Balchem Corporation: Initiation Of Coverage – Will Its Strong Performance in Human Nutrition & Health Continue To Last? 

Balchem Corporation’s sales in fourth quarter 2023 were marked by a slight dip, but the company still posted record operating earnings and free cash flow. It also achieved record fourth-quarter sales and earnings in the Human Nutrition & Health segment. Going back a bit, full year 2023 sales were down 2.1%, yet operational earnings recorded an increase of 9.6%. The company significantly dealt with inflationary pressures over the last few years, returning margins to standard levels. Balchem’s strategic initiatives resulted in full integration of the Kappa Bioscience and Bergstrom Nutrition acquisitions of 2022, which are enhancing its ability to offer a broad array of innovative solutions for customers’ health and nutritional requirements.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!